No headlines found.
No press releases found.
No news found.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Marker Therapeutics trades on the NASDAQ stock market under the symbol MRKR.
As of July 28, 2026, MRKR stock price declined to $1.18 with 20,186 million shares trading.
MRKR has a beta of 1.96, meaning it tends to be more sensitive to market movements. MRKR has a correlation of 0.08 to the broad based SPY ETF.
MRKR has a market cap of $19.67 million. This is considered a Sub-Micro Cap stock.
Last quarter Marker Therapeutics reported $0 in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-665,600 and exceeded earnings estimates by $.03.
In the last 3 years, MRKR traded as high as $8.20 and as low as $.81.
The top ETF exchange traded funds that MRKR belongs to (by Net Assets): VTI, VXF.
MRKR has underperformed the market in the last year with a price return of -24.4% while the SPY ETF gained +17.5%. MRKR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.6% and -19.2%, respectively, while the SPY returned +3.9% and -1.1%, respectively.
MRKR support price is $1.16 and resistance is $1.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRKR shares will trade within this expected range on the day.
